Menopause & Ovarian Aging: When Egg Production Ceases

Menopause = final menstrual period (confirmed after 12 months amenorrhea). Average age 51 (45–55). It marks the end of ovarian follicular activity.

Ovarian Follicular Atresia: The Lifelong Process

  • Peak: 6–7 million oocytes at 20 wks gestation.
  • Birth: 1–2 million.
  • Puberty: 300,000–400,000.
  • Ongoing atresia: ~1,000 follicles lost/month (most by apoptosis, not ovulation).
  • ~37 yrs: ~25,000 – fertility declines notably.
  • ~51 yrs: <1,000 – menopause.

Hormonal Trajectory

  • Perimenopause (2–8 yrs before): FSH rises (loss of inhibin B feedback), estradiol fluctuates wildly, AMH ↓, anovulatory cycles increase.
  • Menopause: Estradiol <20 pg/mL, FSH >30–40 mIU/mL consistently.
  • Postmenopause: Ovarian stroma produces androstenedione → peripheral aromatization to estrone (weak estrogen).

Clinical Implications

  • Vasomotor symptoms: Hot flashes (75–80%), night sweats.
  • Genitourinary syndrome of menopause (GSM): Vaginal atrophy, dyspareunia, recurrent UTI.
  • Bone: Accelerated loss (2–3%/yr × 5–10 yrs) → osteoporosis.
  • Cardiovascular: Loss of estrogen vasoprotection → ↑ LDL, ↓ HDL, endothelial dysfunction.
  • Cognitive/mood: Brain fog, depression/anxiety risk.

Management

  • MHT (hormone therapy): Gold standard for symptoms <60 or <10 yrs post-menopause; individualized risk/benefit.
  • Non-hormonal: SSRIs/SNRIs, gabapentin, fezolinetant (NK3 antagonist), vaginal estrogen (low-dose, safe long-term).
  • Lifestyle: Weight-bearing exercise, Ca/Vit D, smoking cessation, Mediterranean diet.
  • Screening: Bone density (65 or earlier if risk), lipids, diabetes, cancer screening.

Menopause is a transition, not a disease. Proactive care optimizes healthy aging.

Infertility - Related Articles